Considerations for CAR T-Cell Therapy Vs Bispecific Antibodies in Relapsed/Refractory Follicular Lymphoma

Patient preferences should be considered when selecting the optimal treatment regimen for patients with relapsed/refractory follicular lymphoma, as both CD19-directed CAR T-cell therapies and CD20-targeted bispecific antibodies can be efficacious in this population, according to a presentation by Caron A. Jacobson, MD, MMSc, at the 2023 SOHO Annual Meeting.

Related Keywords

Houston ,Texas ,United States ,Carona Jacobson ,Juno Bristol Myers Squibb ,Dana Farber Cancer Institute ,Meeting Of The Society Hematologic Oncology ,Novartis ,Effector Cell Therapy Program ,European Hematology Association ,Genentech ,International Conference On Malignant Lymphoma ,Immune Effector Cell Therapy Program ,Hematology Association ,Bristol Myers Squibb ,Malignant Lymphoma ,Annual Meeting ,Society Hematologic Oncology ,Non Hodgkin Lymphoma ,Follicular Lymphoma ,Cart Cell ,2023 Soho Annual Meeting ,Bispecifics ,